

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the "Market Abuse Regulation") and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.

February 26, 2026
Company announcement No. 03

The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided on the following pages.

Contact information

Investor Relations

| | | |
|---------------------|---------------|--|
| Tobias Bjorklund | +45 3077 8682 | tobb@novonesis.com |
| Anders Enevoldsen | +45 5350 1453 | adev@novonesis.com |
| Louise Pugholm Aabo | | lspa@novonesis.com |

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of
Novonesis Group
Krogshøjvej 36
2880 Bagsvaerd
Denmark

| 1. | Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|-----------|--|--|----------|-----------|-----------|---------------|
| a) | Name | Ester Baiget | | | | |
| 2. | Reason for the notification | | | | | |
| a) | Position/status | CEO and president | | | | |
| b) | Initial notification/ Amendment | Initial notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novozymes A/S | | | | |
| b) | LEI | 529900T6WVNZXD2R3JW38 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the financial instrument, type of instrument | B-Shares | | | | |
| | Identification code | DK0060336014 | | | | |
| b) | Nature of the transaction | Shares received as part of incentive program | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 368.5</td> <td>18,337 shares</td> </tr> </tbody> </table> | Price(s) | Volume(s) | DKK 368.5 | 18,337 shares |
| Price(s) | Volume(s) | | | | | |
| DKK 368.5 | 18,337 shares | | | | | |
| d) | Aggregated information | Number of shares: 18,337 | | | | |
| | - Aggregated volume | Average price, DKK: 368.5 | | | | |
| | - Price | Transaction value, DKK: 6,757,184.50 | | | | |
| e) | Date of transaction | February 25, 2026 | | | | |
| f) | Place of the transaction | Outside a trading venue | | | | |

| 1. | Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|-----------|--|---|----------|-----------|-----------|--------------|
| a) | Name | Rainer Lehmann | | | | |
| 2. | Reason for the notification | | | | | |
| a) | Position/status | CFO and Executive Vice President | | | | |
| b) | Initial notification/ Amendment | Initial notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novozymes A/S | | | | |
| b) | LEI | 529900T6WVNZXD2R3JW38 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the financial instrument, type of instrument Identification code | B-Shares DK0060336014 | | | | |
| b) | Nature of the transaction | Shares received as part of incentive program | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 368.5</td> <td>2,268 shares</td> </tr> </tbody> </table> | Price(s) | Volume(s) | DKK 368.5 | 2,268 shares |
| Price(s) | Volume(s) | | | | | |
| DKK 368.5 | 2,268 shares | | | | | |
| d) | Aggregated information - Aggregated volume - Price | Number of shares: 2,268 Average price, DKK: 368.5 Transaction value, DKK: 835,758.00 | | | | |
| e) | Date of transaction | February 25, 2026 | | | | |
| f) | Place of the transaction | Outside a trading venue | | | | |

| | | |
|----|--|---|
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Anders Lund |
| 2. | Reason for the notification | |
| a) | Position/status | Executive Vice President, Chief Operating Officer |
| b) | Initial notification/ Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Novozymes A/S |
| b) | LEI | 529900T6WVNZXD2R3JW38 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | B-Shares DK0060336014 |
| b) | Nature of the transaction | Shares received as part of incentive program |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | DKK 368.5 |
| | | 11,349 shares |
| d) | Aggregated information - Aggregated volume - Price | Number of shares: 11,349 Average price, DKK: 368.5 Transaction value, DKK: 4,182,106.50 |
| e) | Date of transaction | February 25, 2026 |
| f) | Place of the transaction | Outside a trading venue |

| 1. | Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|-----------|--|---|----------|-----------|-----------|--------------|
| a) | Name | Claus Crone Fuglsang | | | | |
| 2. | Reason for the notification | | | | | |
| a) | Position/status | Executive Vice President, Chief Scientific Officer | | | | |
| b) | Initial notification/ Amendment | Initial notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novozymes A/S | | | | |
| b) | LEI | 529900T6WVNZXD2R3JW38 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the financial instrument, type of instrument | B-Shares | | | | |
| | Identification code | DK0060336014 | | | | |
| b) | Nature of the transaction | Shares received as part of incentive program | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 368.5</td> <td>9,269 shares</td> </tr> </tbody> </table> | Price(s) | Volume(s) | DKK 368.5 | 9,269 shares |
| Price(s) | Volume(s) | | | | | |
| DKK 368.5 | 9,269 shares | | | | | |
| d) | Aggregated information | Number of shares: 9,269 | | | | |
| | - Aggregated volume | Average price, DKK: 368.5 | | | | |
| | - Price | Transaction value, DKK: 3,415,626.50 | | | | |
| e) | Date of transaction | February 25, 2026 | | | | |
| f) | Place of the transaction | Outside a trading venue | | | | |

| 1. | Details of the person discharging managerial responsibilities/person closely associated | | | | | |
|-----------|--|---|----------|-----------|-----------|--------------|
| a) | Name | Morten Enggaard Rasmussen | | | | |
| 2. | Reason for the notification | | | | | |
| a) | Position/status | Executive Vice President, People & Stakeholder Relations | | | | |
| b) | Initial notification/ Amendment | Initial notification | | | | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | |
| a) | Name | Novozymes A/S | | | | |
| b) | LEI | 529900T6WVNZXD2R3JW38 | | | | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | |
| a) | Description of the financial instrument, type of instrument Identification code | B-Shares DK0060336014 | | | | |
| b) | Nature of the transaction | Shares received as part of incentive program | | | | |
| c) | Price(s) and volume(s) | <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 368.5</td> <td>3,775 shares</td> </tr> </tbody> </table> | Price(s) | Volume(s) | DKK 368.5 | 3,775 shares |
| Price(s) | Volume(s) | | | | | |
| DKK 368.5 | 3,775 shares | | | | | |
| d) | Aggregated information - Aggregated volume - Price | Number of shares: 3,775 Average price, DKK: 368.5 Transaction value, DKK: 1,391,087.50 | | | | |
| e) | Date of transaction | February 25, 2026 | | | | |
| f) | Place of the transaction | Outside a trading venue | | | | |

| | | |
|----|--|---|
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Tina Sejersgård Fanø |
| 2. | Reason for the notification | |
| a) | Position/status | Executive Vice President, Planetary Health Biosolutions |
| b) | Initial notification/ Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Novozymes A/S |
| b) | LEI | 529900T6WVNZXD2R3JW38 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | B-Shares DK0060336014 |
| b) | Nature of the transaction | Shares received as part of incentive program |
| c) | Price(s) and volume(s) | Price(s) |
| | | Volume(s) |
| | | DKK 368.5 |
| | | 11,349 shares |
| d) | Aggregated information - Aggregated volume - Price | Number of shares: 11,349 Average price, DKK: 368.5 Transaction value, DKK: 4,182,106.50 |
| e) | Date of transaction | February 25, 2026 |
| f) | Place of the transaction | Outside a trading venue |